NASDAQ$PLRX
Pliant Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Pliant Therapeutics Inc reported a net loss of $43.3 million for the second quarter of 2025.
The company reported a net loss of $43.3 million, or $0.71 per share, for the three months ended June 30, 2025, compared to a net loss of $55.9 million, or $0.92 per share, in the prior year period. Research and development expenses totaled $32.2 million and general and administrative expenses were $13.4 million. Cash, cash equivalents, restricted cash and short-term investments were $264.4 million at quarter end.
- Net loss of $43.3 million for Q2 2025, improved from $55.9 million in Q2 2024
- R&D expenses decreased to $32.2 million from $45.6 million year-over-year
- Cash position of $264.4 million provides runway for ongoing development programs
- Discontinued bexotegrast development in IPF following safety review
Headline financials
Revenue & EPS history
Pliant Therapeutics · Revenue · Quarterly
$0
Forward guidance
Company expects to continue incurring net losses while advancing early-stage pipeline programs following restructuring.
Tailwinds
- Strong cash position of $264.4 million
- Restructuring expected to extend cash runway
Headwinds
- Continued net losses anticipated for foreseeable future
- Discontinuation of lead program increases development risk
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-1.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-4.2%
Avg return
30 days after
36%
9 / 25 earnings
Positive
+12.1%
Q3 2019
Best reaction
-11.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2026 | +0.8% | -4.2% | -4.2% | |
| Q3 2025 | +3.3% | +17.6% | -20.9% | |
| Q1 2025 | -1.5% | -2.9% | -1.4% | |
| Q4 2024 | -11.7% | +17.4% | -5.1% | |
| Q3 2024 | -4.5% | -12.0% | -6.4% | |
| Q2 2024 | -6.5% | -9.6% | -1.8% | |
| Q1 2024 | -1.4% | -1.2% | -13.4% | |
| Q4 2023 | -7.8% | -4.8% | -13.4% | |
| Q3 2023 | -8.0% | -12.4% | -2.7% | |
| Q2 2023 | +3.4% | -0.9% | -9.5% | |
| Q1 2023 | +4.2% | -0.0% | +3.0% | |
| Q4 2022 | -10.9% | -9.4% | -17.6% | |
| Q3 2022 | -6.5% | -6.7% | -14.5% | |
| Q2 2022 | +11.9% | +12.6% | +6.2% | |
| Q1 2022 | -6.8% | -1.8% | +40.5% | |
| Q4 2021 | +3.7% | -9.9% | -26.6% | |
| Q3 2021 | -4.0% | -3.2% | -17.9% | |
| Q2 2021 | -6.5% | -12.4% | -15.7% | |
| Q1 2021 | -0.1% | -14.7% | -3.1% | |
| Q4 2020 | +4.6% | +2.5% | -19.9% | |
| Q3 2020 | +12.1% | +9.9% | +21.2% | |
| Q3 2019 | +12.1% | +9.9% | +21.2% | |
| Q2 2019 | -8.5% | -8.2% | -1.2% | |
| Q4 2019 | -8.5% | -8.2% | -1.2% | |
| Q2 2020 | -8.5% | -8.2% | -1.2% | |
| Q1 2020 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro